{"schema_version":"1.0","type":"article","title":"瘦瘦針、猛健樂之後，減肥藥研發正在發生什麼事？","url":"https://drugnews.com.tw/articles/2026-04-03-dcard-261227197.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-03-dcard-261227197.md","lang":"zh-Hant","date":"2026-04-03","publish_at":"2026-04-03T10:30:00+08:00","updated_at":"2026-04-03","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","GLP-1","BD","臨床數據","生技投資","製藥巨頭"],"summary":"過去幾年，**司美格魯肽（semaglutide）與替爾泊肽（tirzepatide）**幾乎重寫了肥胖治療的市場想像。它們不只把減重從「意志力問題」拉回醫療管理，更把投資人、藥廠與臨床醫師對減重藥的預期，直接拉高到一個全新標準。","key_points":[],"facts":[],"sections":["第一條新主線：胰淀素（amylin）不再只是配角，而是 GLP-1 後時代最像「基礎骨架」的機制","第二條主線：多重腸泌素不再只比減重幅度，而是在比「誰更接近手術級效果」","第三條主線：FGF21 崛起，標誌減重藥開始從「少吃」走向「代謝重塑」","第四條主線：ActRII 路線的真正野心，不是讓你再瘦一點，而是把「減脂不減肌」做成新標準","第五條主線：siRNA 讓減重藥開始有了「低頻維持治療」的未來想像","真正的範式轉移，不是 GLP-1 退位，而是減重這件事終於開始變得更像「精準醫療」"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"Youtube","source":"","date":"","url":""},{"title":"Obesity has emerged as one of the most significant public health challenges of the 21st century, affecting over 42% of United States adults and contributing to substantial morbidity, mortality, and healthcare costs.[1] The recognition of obesity as a chro","source":"","date":"","url":""},{"title":"www.ncbi.nlm.nih.gov","source":"","date":"","url":""},{"title":"\"Obesity Medications: Evidence-Based Management - NCBI\"","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial","source":"","date":"","url":""},{"title":"Eli Lilly.","source":"","date":"","url":""},{"title":"pubmed.ncbi.nlm.nih.gov","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"www.novonordisk.com","source":"","date":"","url":""},{"title":"https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2025/q4-2024-investor-presentation.pdf","source":"","date":"","url":"https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2025/q4-2024-investor-presentation.pdf"},{"title":"www.novonordisk.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight...","source":"","date":"","url":""},{"title":"Agreement allows for a range of potentially best-in-class therapy options as monotherapy and fixed dose combination with Roche`s lead incretin asset CT 388Collaboration will complement Roche's...","source":"","date":"","url":""},{"title":"www.roche.com","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-next-gen-obesity-drug-shows-reduction-blood-sugar-levels-trial-2026-03-19/","source":"","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-next-gen-obesity-drug-shows-reduction-blood-sugar-levels-trial-2026-03-19/"},{"title":"www.reuters.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：瘦瘦針、猛健樂之後，減肥藥研發正在發生什麼事？（圖 1）","url":"https://drugnews.com.tw/assets/articles/dcard-261227197/dcard-01.webp"},{"alt":"Dcard 原圖：瘦瘦針、猛健樂之後，減肥藥研發正在發生什麼事？（圖 2）","url":"https://drugnews.com.tw/assets/articles/dcard-261227197/dcard-02.webp"},{"alt":"Dcard 原圖：瘦瘦針、猛健樂之後，減肥藥研發正在發生什麼事？（圖 3）","url":"https://drugnews.com.tw/assets/articles/dcard-261227197/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/dcard-261227197/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-03）。瘦瘦針、猛健樂之後，減肥藥研發正在發生什麼事？。https://drugnews.com.tw/articles/2026-04-03-dcard-261227197.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-03-dcard-261227197-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}